Payment overview · 2025
General Payments
$117.67
5 reported records · 5 companies
Healthcare provider profile · identity verified
Jessica Stepp, DO
Allopathic & Osteopathic Physicians|Family Medicine · DALLAS, GA · NPI 1114210325
Verified facts
What the public records show
CMS Open Payments records show Jessica Stepp, DO received $117.67 in general payments during 2025 across 5 reported records.
Lilly USA, LLC accounted for 38.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.00 | 38.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.64 | 18.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.47 | 17.4% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17.10 | 14.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.46 | 11.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $72.67 | 4 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.64 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 311 | 101 |
| Lisinopril | Lisinopril | 236 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 179 | 60 |
| Gabapentin | Gabapentin | 174 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 173 | 59 |
| Pravastatin Sodium | Pravastatin Sodium | 166 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 57 |
| Omeprazole | Omeprazole | 155 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 136 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 26 |
| Benazepril Hcl | Benazepril Hcl | 120 | 35 |
| Losartan Potassium | Losartan Potassium | 115 | 36 |
| Metformin Hcl | Metformin Hcl | 102 | 35 |
| Clonazepam | Clonazepam | 101 | 24 |
| Simvastatin | Simvastatin | 99 | 28 |
| Meloxicam | Meloxicam | 94 | 33 |
| Sertraline Hcl | Sertraline Hcl | 94 | 35 |
| Trazodone Hcl | Trazodone Hcl | 88 | 33 |
| Tramadol Hcl | Tramadol Hcl | 84 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 14 |
| Atenolol | Atenolol | 61 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 15 |
| Potassium Chloride | Potassium Chloride | 53 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | suppressed |
| Bupropion Xl | Bupropion Hcl | 51 | 15 |
| Furosemide | Furosemide | 51 | 23 |
| Famotidine | Famotidine | 49 | 19 |
| Buspirone Hcl | Buspirone Hcl | 47 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 17 |
| Allopurinol | Allopurinol | 46 | 17 |
| Alprazolam | Alprazolam | 46 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | suppressed |
| Glimepiride | Glimepiride | 44 | 17 |
| Ozempic | Semaglutide | 43 | suppressed |
| Eliquis | Apixaban | 41 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 14 |
| Metformin Hcl Er | Metformin Hcl | 41 | 17 |
| Prednisone | Prednisone | 40 | 33 |
| Carvedilol | Carvedilol | 39 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $117.67 · 5 records | Lilly USA, LLC | ABRYSVO, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, PREVNAR 20, TZIELD | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error